文献速递胸部肿瘤

阿替利珠单抗对比多西他赛治疗经治NSCLC:POPLAR与OAK最终结果

Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials.
PubMed 文献 · J Thorac Oncol · 2020-11-06

POPLAR(2期,287例)与OAK(3期,1225例)评估经治晚期NSCLC患者使用阿替利珠单抗对比多西他赛的长期获益。最终分析显示阿替利珠单抗组总生存优于多西他赛,且在各PD-L1表达与组织学亚组中一致,未发现新安全性信号。

要点

  • 经治晚期NSCLC中阿替利珠单抗较多西他赛显示持续总生存获益
  • 生存获益在各PD-L1表达水平与组织学类型中一致
  • 长期随访未见新的安全性信号

核心结论

  • 长期随访显示,经治NSCLC患者中阿替利珠单抗对比多西他赛具有持续且一致的总生存获益,不受PD-L1表达、组织学或后续免疫治疗影响。

研究设计与样本

  • POPLAR为2期随机研究,随机287例(阿替利珠单抗144例,多西他赛143例)。
  • OAK为3期随机研究,随机1225例(阿替利珠单抗613例,多西他赛612例)。
  • 给药方案为阿替利珠单抗1200 mg固定剂量或多西他赛75 mg/m2,每3周一次。

主要发现

  • POPLAR中位OS为12.6个月对比9.7个月,HR=0.76(95%CI:0.58-1.00)。
  • OAK中位OS为13.3个月对比9.8个月,HR=0.78(95%CI:0.68-0.89)。
  • POPLAR4年OS率分别为14.8%(8.7-20.8)与8.1%(3.2-13.0)。
  • OAK4年OS率分别为15.5%(12.4-18.7)与8.7%(6.2-11.3)。
  • 多西他赛组4年生存者中多数后续接受免疫治疗(POPLAR 50%,OAK 65%)。

关键数值与推荐

  • POPLAR与OAK中阿替利珠单抗较多西他赛的OS改善分别达p=0.04与p=0.0003(原文引言所述)。
  • 4年生存者中阿替利珠单抗组治疗相关3/4级不良事件发生率POPLAR为27%、OAK为16%。

临床怎么用

  • 对经治晚期NSCLC,阿替利珠单抗可作为多西他赛的替代选择,无需按PD-L1表达或组织学筛选。
  • 长期生存者比例虽低但可见,治疗决策需结合后续免疫治疗可及性。

局限性

  • 4年生存者人数少,亚组描述为探索性。
  • 多西他赛组部分长期生存者后续接受免疫治疗,可能影响组间比较解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The phase 2 POPLAR and phase 3 OAK studies of the anti-programmed death-ligand 1 (PD-L1) immunotherapy atezolizumab in patients with previously treated advanced NSCLC revealed significant improvements in survival versus docetaxel (p = 0.04 and 0.0003, respectively). Longer follow-up permits evaluation of continued benefit of atezolizumab. This study reports the final overall survival (OS) and safety findings from both trials. METHODS: POPLAR randomized 287 patients (atezolizumab, 144; docetaxel, 143) and OAK randomized 1225 patients (atezolizumab, 613; docetaxel, 612). The patients received atezolizumab (1200 mg fixed dose) or docetaxel (75 mg/m2) every 3 weeks. Efficacy and safety outcomes were evaluated. RESULTS: A longer OS was observed in patients receiving atezolizumab versus docetaxel in POPLAR (median OS = 12.6 mo versus 9.7 mo; hazard ratio = 0.76, 95% confidence interval [CI]: 0.58-1.00) and OAK (median OS = 13.3 versus 9.8 mo; hazard ratio = 0.78, 95% CI: 0.68-0.89). The 4-year OS rates in POPLAR were 14.8% (8.7-20.8) and 8.1% (3.2-13.0) and those in OAK were 15.5% (12.4-18.7) and 8.7% (6.2-11.3) for atezolizumab and docetaxel, respectively. Atezolizumab had improved OS benefit compared with docetaxel across all PD-L1 expression and histology groups. Most 4-year survivors in the docetaxel arms received subsequent immunotherapy (POPLAR, 50%; OAK, 65%). Of the 4-year survivors, most had Eastern Cooperative Oncology Group performance status of 0 and nonsquamous histological classification and approximately half were responders (POPLAR: atezolizumab, seven of 15; docetaxel, three of four; OAK: atezolizumab, 24 of 43; docetaxel, 11 of 26). Treatment-related grade 3/4 adverse events occurred in 27% and 16% of atezolizumab 4-year survivors in POPLAR and OAK, respectively. CONCLUSIONS: Long-term follow-up suggests a consistent survival benefit with atezolizumab versus docetaxel in patients with previously treated NSCLC regardless of PD-L1 expression, histology, or subsequent immunotherapy. Atezolizumab had no new safety signals, and the safety profile was similar to that in previous studies.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Mazieres J, Rittmeyer A, Gadgeel S, et al. Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials. J Thorac Oncol. 2020. PMID: 33166718. doi:10.1016/j.jtho.2020.09.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。